Search

Your search keyword '"Vera A Bittner"' showing total 21 results

Search Constraints

Start Over You searched for: Author "Vera A Bittner" Remove constraint Author: "Vera A Bittner"
21 results on '"Vera A Bittner"'

Search Results

1. Depression symptom patterns as predictors of metabolic syndrome and cardiac events in symptomatic women with suspected myocardial ischemia: The women's ischemia syndrome evaluation (WISE and WISE-CVD) projects

2. ST-Segment Elevation Myocardial Infarction in a Young Woman

3. Risk of Major Adverse Cardiovascular Events and Major Hemorrhage Among White and Black Patients Undergoing Percutaneous Coronary Intervention

4. Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction

5. Lipoprotein(a) and the Effect of Alirocumab on Revascularization Following Acute Coronary Syndrome

6. Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes

7. Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial

8. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

9. The Projected Impact of Population-Wide Achievement of LDL Cholesterol70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD

10. Sex, Prescribing Practices and Guideline Recommended, Blood Pressure, and LDL Cholesterol Targets at Baseline in the BARI 2D Trial

11. Effect of Alirocumab on Mortality After Acute Coronary Syndromes

12. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

13. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

14. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial

15. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

16. Abstract P155: Risk for Recurrent Events Among Patients Receiving Intensive Medical Management Following Myocardial Infarction

17. 100 Questions & Answers About Managing Your Cholesterol

18. Association of Race and Sex With Risk of Incident Acute Coronary Heart Disease Events

19. Abstract 3403: Heart Failure Patients Improve their Exercise Capacity after Cardiac Rehabilitation Irrespective of having a Preserved or Depressed Ejection Fraction

20. Correlates of high HDL cholesterol among women with coronary heart disease

21. Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial

Catalog

Books, media, physical & digital resources